|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
35,915,000 |
Market
Cap: |
5.05(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$36.74 - $145.96 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile TransMedics Group is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across various disease states. Co. has developed the Organ Care System (OCS), a portable organ perfusion and monitoring system that using Co.'s technology to replicate near-physiologic conditions for donor organs outside of the human body. The OCS was designed to perfuse donor organs with warm, oxygenated and nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. Co.'s OCS products are one for each of lung, heart and liver transplantations.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
2,500 |
2,500 |
Total Buy Value |
$0 |
$0 |
$155,000 |
$155,000 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
406,079 |
504,936 |
581,965 |
1,242,554 |
Total Sell Value |
$46,236,617 |
$54,479,102 |
$60,237,739 |
$97,463,776 |
Total People Sold |
7 |
7 |
8 |
11 |
Total Sell Transactions |
28 |
43 |
55 |
134 |
End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Lung Biotechnology Pbc |
10% Owner |
|
2019-12-09 |
4 |
S |
$18.75 |
$9,375,000 |
I/I |
(500,000) |
2,053,240 |
|
- |
|
Carey John F |
VP of Operations |
|
2019-11-15 |
4 |
OE |
$0.28 |
$336 |
D/D |
1,200 |
1,200 |
|
- |
|
Sullivan John F |
VP of Quality & Engineering |
|
2019-11-15 |
4 |
OE |
$0.28 |
$392 |
D/D |
1,400 |
10,828 |
|
- |
|
Weill David |
Director |
|
2019-11-11 |
4 |
B |
$17.00 |
$170,000 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
Afeyan Noubar |
10% Owner |
|
2019-10-29 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,840,191) |
0 |
|
- |
|
Kania Edwin M Jr |
Director |
|
2019-10-29 |
4 |
A |
$0.00 |
$0 |
D/D |
120,595 |
153,928 |
|
- |
|
Khayal Tamer I |
Chief Commercial Officer |
|
2019-08-09 |
4 |
OE |
$0.28 |
$364 |
D/D |
1,300 |
46,076 |
|
- |
|
Hassanein Waleed H |
President & CEO |
|
2019-08-09 |
4 |
OE |
$0.28 |
$1,680 |
D/D |
6,000 |
115,429 |
|
- |
|
Hassanein Waleed H |
President & CEO |
|
2019-06-13 |
4 |
OE |
$0.28 |
$1,120 |
D/D |
4,000 |
109,429 |
|
- |
|
Lung Biotechnology Pbc |
10% Owner |
|
2019-05-06 |
4 |
A |
$0.00 |
$0 |
I/I |
2,553,240 |
2,553,240 |
|
- |
|
Gordon Stephen |
Chief Financial Officer |
|
2019-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
28,571 |
28,571 |
|
- |
|
Gordon Stephen |
Chief Financial Officer |
|
2019-05-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(100,000) |
0 |
|
- |
|
Khayal Tamer I |
Chief Commercial Officer |
|
2019-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
44,776 |
44,776 |
|
- |
|
Khayal Tamer I |
Chief Commercial Officer |
|
2019-05-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(156,719) |
0 |
|
- |
|
Tobin James R |
Director |
|
2019-05-06 |
4 |
A |
$0.00 |
$0 |
I/I |
291,948 |
434,805 |
|
- |
|
Tobin James R |
Director |
|
2019-05-06 |
4 |
A |
$0.00 |
$0 |
I/I |
142,857 |
142,857 |
|
- |
|
Tobin James R |
Director |
|
2019-05-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(500,000) |
0 |
|
- |
|
Sullivan John F |
VP of Quality & Engineering |
|
2019-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
9,428 |
9,428 |
|
- |
|
Sullivan John F |
VP of Quality & Engineering |
|
2019-05-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(33,000) |
0 |
|
- |
|
Basile Edward M |
Director |
|
2019-05-06 |
4 |
B |
$16.00 |
$136,000 |
D/D |
8,500 |
22,814 |
2.39 |
- |
|
Basile Edward M |
Director |
|
2019-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
14,314 |
14,314 |
|
- |
|
Riva Capital Management Iii, Llc |
10% Owner |
|
2019-05-06 |
4 |
A |
$0.00 |
$0 |
I/I |
3,499,859 |
3,499,859 |
|
- |
|
Kania Edwin M Jr |
Director |
|
2019-05-06 |
4 |
B |
$16.00 |
$533,328 |
D/D |
33,333 |
33,333 |
2.39 |
- |
|
Kania Edwin M Jr |
Director |
|
2019-05-06 |
4 |
A |
$0.00 |
$0 |
I/I |
881,118 |
57,142 |
|
- |
|
Kania Edwin M Jr |
Director |
|
2019-05-06 |
4 |
A |
$0.00 |
$0 |
I/I |
370,831 |
7,511 |
|
- |
|
388 Records found
|
|
Page 15 of 16 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|